Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment

Veterinary Immunology and Immunopathology

Volumn 71, Issue 1, 1999, Pages 69-76

  Rhalem, Abdelkebir ^a   Sahibi, Hamid ^a   Lasri, Saâdia ^a   Jaffe, Charles L ^b  

^a INSTITUT AGRONOMIQUE ET VÉTÉRINAIRE HASSAN II   (Morocco)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Dimethasulfonate pentamidine; Dog; Immunity; Leishmania infantum; Treatment

Indexed keywords

PARASITE ANTIGEN; PENTAMIDINE MESYLATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, CELLULAR; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; METALLOENDOPEPTIDASES; PENTAMIDINE; PROTOZOAN PROTEINS; TRYPANOCIDAL AGENTS;

EID: 0032852925     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2427(99)00088-4     Document Type: Article

References (26)

1. Abranches P., Silva-Pereira M.C., Conceicao-Silva F.M., Santos-Gomez G.M., Janz J.G. Canine leishmaniasis: Pathological and ecological factors influencing transmission of infection. J. Parasitol. 77:1991;557-561.
2. Abranches P., Santos-Gomes G., Rachamim N., Campino L., Schnur L.F., Jaffe C.L. An experimental model for canine visceral leishmaniasis. Parasite Immunol. 13:1991;537-550.
3. Adler, S., 1936. Canine visceral leishmaniasis with special reference to its relationship to human visceral leishmaniasis. In: 3e congress International de pathologie comparée, Section Medicine Humaine, Eleftheroudakis Co., Athens, pp. 1-10.
4. Alvar J., Molina R., San Andres M., Tesouro M., Neito J., Vitutia M., Gonzales F., San Andres M.D., Boggio J., Rodriguez F., Sainz A., Escacena C. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88:1994;371-378.
5. Berman J.D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10:1988;560-586.
6. Berrag, B., Sahibi, H., Guessous Idrissi, N., Rhalem, A., 1996. The severity of Leishmania infantumin naturally infected dogs in Morocco. 45th Annual meeting of the Am., Soc. Trop. Med. Hyg. 55: 288-289.
7. Bettini S., Gradoni L. Canine leishmaniasis in the Mediterranean area and its implications for human leishmaniasis. Insect. Sci. Applic. 7:1986;241-245.
8. Bouvier J., Etges R.J., Bordier C. Identification and purification of membrane and soluble forms of the major surface protein of Leishmania promastigotes. J. Biol. Chem. 260:1985;15504-15509.
9. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
10. Bravo L., Frank L.A., Brenneman K.A. Canine leishmaniasis in the United States. Small Animal Parasitol. 15:1993;699-708.
11. Carter, K.C., Banduwardene, R., Mullen, A., 1996. The effect of drug treatment on antibody and cell-mediated responses of Leishmania donovani infected BALB/C mice. EMOP VII Abstracts. Parasitologia 38(1-2).
12. Champsi J., Mcmahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56:1988;3272-3279.
13. Delmont J. Les leishmanioses La gazette de l'étudiant. Gaz. Méd. de France. 90:1983;2857-2868.
14. Denerolle P. Leishmaniose canine: difficultés du diagnostic et du traitement (125 cas). Prat. Méd. Chir. Anim. Comp. 31:1996;137-145.
15. Ferrer L., Aisa M.J., Roura X., Portus M. Serological diagnosis and treatment of canine leishmaniasis. Vet. Record. 136:1995;514-516.
16. Gradoni L., Maroli M., Gramiccia M., Mancianti F. Leishmania infantuminfection rates in phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med. Vet. Entomol. 1:1987;339-342.
17. Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans. Roy. Soc. Trop. Med. Hyg. 84:1990;673-675.
18. Jahn A., Diesfield H.J. Evaluation of a visually read ELISA for serodiagnosis and seroepidemiological studies of Kala-azar in the Baringo District, Kenya. Trans. Roy. Soc. Trop. Hyg. 77:1983;451-454.
19. Jaffe C.L., Keren E., Nahary O., Rachamim N., Schnur L. Canine visceral leishmaniasis at Wadi Hamam in Israel. Trans. Roy. Soc. Trop. Med. Hyg. 82:1988;852-853.
20. Mansueto S., Miceli M.D., Quartararo P. Counter immunoelectrophoresis (CIEP) and ELISA tests in the diagnosis of canine leishmaniasis. Ann. Trop. Med. Parasitol. 76:1982;229-231.
21. Peters, W., Killick-Kendrick, R. (Eds.), 1987. The Leishmaniasis in Biology and Medicine, vol. I and II. Academic Press, New York, 941 p.
22. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernardina W., Real G.D., Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect. Immun. 2:1994;229-235.
23. Rhalem A., Sahibi H., Guessous I.N., Lasri S., Natami A., Riyad M., Berrag B. Immune response against Leishmania antigens in dogs naturally and experimentally infected with Leishmania infantum. Vet. Parasitol. 81:1999;173-184.
24. Riera, C., Valladares, J.E., Galleco, M., Aisa, M.J., Castillejo, S., Fisa, R., Torras, S., de Colmenares, M., Alberola, J., Arboix, M., Portus, M., 1996. Experimental model of canine leishmaniasis. Serological and parasitological follow-up before, and after, chemotherapy. EMOP VII Abstracts. Parasitologia 38(1-2).
25. Russell, D.G., Wright, S.O., 1988. Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes. J. Exp. Med. 168: 279-292.
26. Slappendel R.J. Canine leishmaniasis: a review based on 95 cases in the Netherlands. Vet Q. 10:1988;1-15.